Estrogens can reduce the effects of testosterone by increasing the hepatic production and in turn circulating levels of sex hormone-binding globulin (SHBG), a carrier protein that binds to and occupies androgens like testosterone and DHT, and thereby reducing free concentrations of these androgens. However, estradiol exerts negative feedback on the hypothalamic–pituitary–gonadal axis and, for this reason, prevention of its formation can reduce this feedback and disinhibit gonadal production of testosterone, which in turn can increase levels of endogenous testosterone. As only a very small fraction of testosterone is converted into estradiol, this does not affect testosterone levels, but it can prevent estrogenic side effects like gynecomastia that can occur when testosterone is administered at relatively high dosages. On the other hand, 5α-reductase inhibitors may prevent or reduce adverse androgenic side effects of testosterone like scalp hair loss, oily skin, acne, and seborrhea. Due to lack of controlled evaluations in women and potential virilizing effects,AVEEDis not indicated for use in women see CONTRAINDICATIONS and Use In Specific Populations. Patients should be informed of this possible risk when deciding whether to use or to continue to use AVEED. If a venous thromboembolic event is suspected, discontinue treatment with AVEED and initiate appropriate workup and management. If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable level. AVEED is available only through a restricted program called the AVEED REMS Program because of the risk of serious POME and anaphylaxis. Androgens traditionally cannot be given orally due to poor bioavailability from extensive hepatic first-pass metabolism . There was no significant change to PSA levels noted in the T patch group; baseline levels were measured to be (0.89±0.10) ng/mL, and on day 90, the PSA levels were (0.88±0.09) ng/mL . Cavender et al. performed a case study where such an incident occurred in a 10-month-old male. Also, it is important to note that women and children should avoid contact with clothing or skin that may have gel residue due to reported side effects such as precocious puberty caused by secondary transfer. Testosterone gels are more commonly used as treatment modalities for hypogonadism due to their ease of use and patient preference. The drug is a prodrug of testosterone, the biological ligand of the androgen receptor (AR) and hence is an androgen and anabolic steroid. In November 2003, Nebido, an injectable testosterone undecanoate formulation made by Schering AG, received its initial European approval in Finland. Testosterone undecanoate is metabolized partially in the intestinal wall into 5-alpha-dihydrotestosterone undecanoate (DHTU). It is absorbed through the lymphatic system (90-100%) and peak serum levels are reached after about 3-5 hours. This bioavailability is increased with food, especially foods containing fat, thus it is typically recommended to be taken with a meal. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Do not be alarmed by this list of possible side effects. Abuse of this medicine can cause serious health problems, especially if you take too much testosterone alone or with other androgenic anabolic steroids. In a few patients diarrhoea and stomach pain or discomfort have been reported during the use of this medicine.
